EuroEyes International Eye Clinic

Focusing On Presbyopia Treatments May Open New Markets But Faces Competition And Economic Uncertainties

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

09 Feb 25

Updated

26 Mar 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-25.1%

-0.9%

-25.1%

-0.9%

You can edit this narrative until May 12 5:59 AM. Then, changes will post as Updates.

Author's Valuation

HK$6.3150.4% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates3

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

HK$6.31

50.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.00%

Healthcare Services revenue growth rate

0.22%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.19%

Calculation

HK$124.32m

Earnings '28

20.04x

PE Ratio '28

HK$2.49b

Market Cap '28

HK$2.49b

Market Cap '28

331.52m

No. shares '28

HK$7.51

Share Price '28

HK$7.51 Share Price '28

Discounted to 2025 @ 6.00% p.a.

HK$6.31

Fair Value '25